What do you think about their strategy to take the non-FDA...

What do you think about their strategy to take the non-FDA pathway, rather opting for the lab network pathway in the US? Their argument was that the non-FDA route would be a faster way to commercialisation and importantly generating revenue. Basically, all we know they is that they set-up a business entity in the US and have someone on the ground there looking to make a deal with a partner, however that amounted to nothing - merely empty promises about waiting for “the right” partner to launch in the US. I have always doubted their US market strategy - particularly given the TGA is already quite a stringent process, I would have thought submitting a concurrent FDA application might have been a more robust pathway to approval/commercialisation or even interest from big pharma.
It seems to me that it’s not just Otto but others who need the boot… I can see why they may support him particularly for someone on one big junket in the US.